Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, shared a post on X:
“Lean body mass–based oxaliplatin dosing reduces peripheral neuropathy in stage III colon cancer without compromising survival!
Lower rates of grade ≥2 oxaliplatin-induced peripheral neuropathy.
Better quality of life.
No impact on relapse-free survival or overall survival.
Proof-of-concept randomized trial.”
Title: Impact of Lean Body Mass–Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial
Authors: Eric Assenat, Meher Ben Abdelghani, Sophie Gourgou, Hervé Perrier, Faiza Khemissa Akouz, Romain Desgrippes, Marie-Pierre Galais, Chloé Janiszewski, Thibault Mazard, Yves Rinaldi, Côme Lepage, Raphael Tetreau, Pierre Senesse
Read The Full Article at Journal of Clinical Oncology.
More posts featuring Colon Cancer.